Find Clinical Trials

Inclusion Criteria: * Diagnosis of mild to moderate open-angle glaucoma or ocular hypertension * Planned removal of cataract * Female participants of childbearing potential must have a negative urine pregnancy test at the baseline visit and agree to the use of contraception Exclusion Criteria: * Uncontrolled systemic disease * History of incisional/refractive corneal surgery * Any glaucoma diagnosis other than OHT, open-angle, pseudoexfoliative, or pigmentary glaucoma * History of incisional glaucoma surgery or intraocular injections * Other ocular diseases, pathology, or conditions

Inclusion Criteria: * Part 1A: Participants with histologically or cytologically confirmed advanced, metastatic breast cancer and other solid tumors who have exhausted, are intolerant of all available standard of care therapies, and/or without available standard of care therapies. * Part 1B and Part 2A: Participants with advanced breast cancer with 1 to 3 prior lines of systemic therapy in the metastatic setting. Prior lines in the advanced/ metastatic setting may not exceed 2 lines of chemotherapy (inclusive of antibody-drug conjugate with cytotoxic payload). * Parts 2B and 2C: Participants with advanced breast cancer enrolled in regions where cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are not approved and/or not available as the first-line treatment and who are CDK4/6 inhibitor treatment naïve and did not receive any previous systemic treatment for advanced disease. * Participants with breast cancer must have histologically or cytologically confirmed advanced breast cancer at the time of most recent testing, based on American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines. * Female participants with metastatic breast cancer must be postmenopausal or receiving ovarian function suppression treatment. * Measurable disease as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1. * Stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Adequate organ function. Exclusion Criteria: * Prior exposure to KAT6A/B or KAT7 inhibitors/degraders. * Patients with active leptomeningeal disease or uncontrolled, untreated brain metastasis. * Participants with any malignancy ≤ 3 years before screening for the study except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively which in the opinion of the investigator is unlikely to require intervention during the study. Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Inclusion Criteria: Model A (patient participants) * Age \> 50 years * Fluent in Danish * Minimum of 7 years of schooling * A diagnosis of either MCI or AD, given at the SUH memory clinic within 6 months before enrollment Model A (cognitively healthy controls) * Age \> 50 years * Fluent in Danish * Minimum of 7 years of schooling Model B: * Age \> 50 years * Fluent in Danish * Minimum of 7 years of schooling Exclusion Criteria: Model A: Patients: * Significantly impaired vision or hearing (to the extent that the patient cannot participate in the AI analysis) * MMSE score \< 16 * Concomitant diagnoses which are expected to influence cognitive impairment (eg. depression) * Patients unable to give consent * Patients with alcohol consumption \>21 standard alcohol units per week * Any history of speech or language impairment predating the current condition Cognitively healthy controls: * Significantly impaired vision or hearing (to the extent that the patient cannot participate in the AI analysis) * MMSE \< 26 and ACE \< 90 * Clinical, laboratory, or neuroradiological findings that could affect cognitive functions * Known diseases which are expected to impair cognitive functions * Any history of speech or language impairment predating the current condition * Patients with alcohol consumption \>21 standard alcohol units per week. Model B: * Significantly impaired vision or hearing (to the extent that the patient cannot participate in the AI analysis) * MMSE score \< 16 * Patients unable to give consent * Patients with concomitant psychosis or severe psychiatric comorbidities other than depression * Any history of speech or language impairment predating the current condition

Inclusion criteria * ≥ 18 years of age * Undergoing chemotherapy and experiencing nausea despite adherence to the prescribed antiemetic regimen * Understands and speaks Danish * Written and orally informed consent * Planned for treatment every 14 days * At least two chemotherapy cycles planned at the time of inclusion Exclusion Criteria: * Brain metastases * Performance status \>2

Inclusion Criteria: * Participant must have locally advanced/unresectable or metastatic Hormone Receptor (HR) positive, Human Epidermal growth factor receptor 2 (HER2) negative breast cancer as defined by the 2010 American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines (estrogen receptor \[ER\] and/or progesterone receptor \[PR\] \>1% and HER2 negative by immunohistochemistry \[IHC\] and/or fluorescent in situ hybridization \[FISH\]). * Participant must have received and progressed on or are intolerant to all therapies known to confer overall survival benefit, including at least one line of endocrine + CDK4/6 inhibitor therapy AND one line of cytotoxic such as chemotherapy and/or antibody drug conjugates (ADCs). * Participant must be a woman ≥ 22 years old and must be able to understand and sign an informed consent form. * Participant must have a life expectancy of at least 3 months. * Participant must have an Eastern Cooperative Oncology Group (ECOG) performance score of 0-2. * it is not known what effects this treatment has on human pregnancy or development of the embryo or fetus. Therefore, women of childbearing potential must agree to avoid becoming pregnant starting at initiation of treatment up until at least 30 days after the last TheraBionic P1 session. * Participants must meet one of the following: * Surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy) * Post-menopausal, defined as no menses for at least 12 months prior to the screening visit without alternative medical causation. * Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the participant. Periodic abstinence methods such as calendar, ovulation, symptothermal, or post ovulation tracking are not acceptable. * Not in a sexual relationship in which they may become pregnant (i.e. same-sex relationship) * If they are of childbearing potential, agree to use at least one method of contraception. Withdrawal is not an acceptable contraceptive method. Exclusion Criteria: * Participants with known active secondary malignancy, unless, in the opinion of the investigator, it is unlikely to interfere with the safety and efficacy of the endpoints * Participants that are taking any other investigational drugs. * Participants that are pregnant or breastfeeding. If a breastfeeding participant would like to be part of this study, breastfeeding must be discontinued. * Participants with active oral mucosal inflammation, ulceration, or other pathology that could interfere with the use of TheraBionic P1 device (for example: mucositis, thrush, bleeding mucosal lesions, oral herpes, aphthous stomatitis, mouth ulcers, chancre sores, gingivostomatitis, herpangina, aphthae). * Participants receiving calcium channel blockers and any agent blocking L-type or T-type voltage gated calcium channels (for example: amlodipine, nifedipine, ethosuximide, ascorbic acid/vitamin C, etc.) unless their medical treatment is discontinued at least one day prior to treatment. Participant must agree to abstain from using calcium channel blockers for the duration of treatment on study. * Participants that do not agree to be followed according to the study protocol or have cognitive or physical inability to use the device.

Inclusion Criteria: 1. Signed informed consent. 2. Men and women aged 18-80 years, inclusive. 3. Confirmed diagnosis of T2DM according to recognized diagnostic criteria 4. Most recent recorded hemoglobin A1c (HbA1c) \> 6.5%. 5. Body Mass Index (BMI) greater than 27 kg/m². Exclusion Criteria: 1. Failure to meet the diagnostic criteria for T2DM in the screening laboratory tests. 2. Being dependent for basic activities of daily living (Barthel score ≤ 90 points). 3. Lack of willingness to cooperate with the follow-up of the lifestyle intervention plan. 4. Presence of serious or terminal comorbidities significantly worsening short- to medium-term prognosis (active cancer, terminal chronic diseases, myocardial infarction within the last 6 months, acute heart failure or NYHA stage ≥ III, etc.). 5. History of ketoacidosis. 6. Presence of criteria or potential autoimmune insulinopenia (abnormal C-peptide, anti-GAD+ antibodies, pattern of basal and/or glucose-stimulated hypoinsulinemia). 7. Cognitive impairment. 8. Weight loss exceeding 5 kg in the past 6 months. 9. Significant changes in physical activity and/or dietary patterns in the past 6 months. 10. History of eating disorders. 11. History of substance abuse. 12. History of severe psychiatric disorders. 13. Pregnancy or intention to become pregnant within the study period.

Inclusion Criteria: * Must meet diagnostic and statistical manual of mental disorders (5th edition) (DSM-5) diagnostic criteria for major depressive disorder (MDD) based upon clinical assessment and confirmed by the mini-international neuropsychiatric interview for children and adolescents (MINI-KID) * Must have a clinical global impression - severity of suicidality - revised (CGI-SS-R) score of "Markedly" or greater (that is, greater than or equal to \[\>=\] 4) at both screening and baseline (predose) visits * Must have a children's depression rating scale - revised (CDRS-R) total score \>= 58 at baseline (predose) * In the physician's opinion, acute psychiatric hospitalization is clinically warranted due to subject's acute suicidality * Must be medically stable based on physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening Exclusion Criteria: * Participant has a current DSM-5 diagnosis of bipolar (or related disorders), intellectual disability, autism spectrum disorder, conduct disorder, oppositional defiant disorder * Participant currently meets DSM-5 criteria for borderline personality disorder * Participant has a current or prior DSM-5 diagnosis of a psychotic disorder, or MDD with psychosis * Participant has a history of seizure disorder * Participant has known allergies, hypersensitivity, intolerance or contraindications to midazolam, esketamine or ketamine, or their excipients

Inclusion Criteria: * An authorization from MHS drugs authorization center for benralizumab, with a diagnosis of asthma (ICD-9 code 493.X and the corresponding internal MHS diagnosis codes for SA). Having an authorization indicates that patients have severe eosinophilic asthma and fulfil the GINA definition of severe asthma as well as additional local reimbursement criteria. * At least one purchase of benralizumab for the first time between January 1 2019 and March 31 2024. * Age ≥18 years on the index date. * MHS members for at least 12 months before the index date. Exclusion Criteria: • Patients who received benralizumab for indication other than asthma according to MHS drugs authorization center. \- currently or recently included in a clinical trial according to the ICD-9 diagnosis code V70.7) and the corresponding internal MHS codes

Inclusion Criteria: * Over the age of 18 * Early breast cancer patients who have had breast surgery with curative intent * Radiotherapy completed ≥ 6 months previously * In remission with no sign of active local disease * Registering a score of ≥3 on perceived pain intensity or pain burden on a 10-point numerical rating scale (NRS) * English speaking and able to communicate reasonably well * Able to give informed consent * Willing to attend for regular treatment at RLHIM Exclusion Criteria: * History of post-breast surgery wound complications * History of breast surgery unrelated to breast cancer treatment * History of previous ScarWork therapy * Diagnosis of lymphoedema * Severe co-morbidities or cognitive disability * Receiving physiotherapy for post-breast surgery pain syndrome at the time of trial

Inclusion Criteria: * Age at the beginning of the study 0-17 years old * Clinical indication and qualification by the attending physician for fiberoptic bronchoscopy under general anesthesia: * Obstruction of the airways: * Suspicion of foreign body aspiration * Persistent stridor * Abnormal result of functional tests of respiratory system - flattening of inspiratory or expiratory curve, presence of restriction (tested vital capacity \<5 percentile) or irreversible obstruction (persistence of Tiffneau index \<5 percentile despite administration of bronchodilators) * Radiological findings located in the course of the larynx, trachea or bronchi * Persistent atelectasis on subsequent radiological examinations * Persistent cough \>4 weeks * Hemoptysis * Suspected laryngomalacia or tracheobronchomalacia * Suspected tracheoesophageal fistula * Persistent dyspnea unresponsive to anti-asthmatic treatment used for min. 2 months, with no other identifiable causes * Radiologically detected mediastinal abnormalities * Suspected presence of a vascular ring * Presence of excessive secretions that are impossible for the patient to expectorate * Fine needle biopsy of cystic lesions * Obtained consent from patient/legal guardian for participation in the study Exclusion Criteria: * Active acute respiratory infection up to 4 weeks before the procedure * Taking antibiotics or systemic glucocorticosteroids up to 4 weeks before the procedure * Patients with very severe comorbidities (congenital immunodeficiencies, genetic disorders, neurological or neuromuscular diseases, cancer, severe congenital heart defects, heart failure, liver failure, inflammatory bowel disease, celiac disease) * Patients with blood clotting disorders * Children with diagnosed respiratory diseases other than asthma and protracted bacterial bronchitis - including interstitial diseases, tuberculosis, inflammation of small and medium-sized blood vessels * Patients for whom \>48 hours have passed between suspicion of foreign body aspiration and interventional bronchoscopy * Children with foreign body aspiration having a foreign body located in the trachea

Inclusion Criteria: * women with invasive breast cancer * live in 59 counties in North Carolina Exclusion Criteria: * women with ductal carcinoma in situ (DCIS) * live outside of 59 counties of North Carolina

Inclusion Criteria: * Have type 2 diabetes * Are receiving ≥20 units of basal insulin per day and ≤55 units/day and ≤1.5 units/kg/day at screening * Have hemoglobin A1c (HbA1c) 7.5% to 10.5% inclusive * Have a body mass index (BMI) of 20 or higher and less than 35 kilograms per square meter (kg/m2) Exclusion Criteria: * Have type 1 diabetes

Inclusion Criteria: * Postpartum individuals * ≥18 years old * Hypertensive disorder of pregnancy * Enrolled in Women and Infants Hospital Hypertension Equity remote monitoring program. Exclusion Criteria: * Maternal cardiac disease * Individuals with pre-pregnancy hypertension or diabetes * Allergy or contraindication to enalapril

Inclusion Criteria: * Patients with histologically or cytologically confirmed triple-negative breast cancer (TNBC). * Subjects with locally recurrent or metastatic advanced TNBC who have progressed after first-line or later-line therapy. * Presence of at least one measurable lesion according to RECIST V1.1 criteria. * ECOG Performance Status 0 or 1. * Life expectancy \>3 months. * Adequate organ and hematopoietic function based on the laboratory tests. * Voluntarily sign the informed consent form. Exclusion Criteria: * History of severe allergy or hypersensitivity to the investigational product or its excipients or drugs of similar chemical class (e.g., monoclonal antibodies), or contraindications to the investigational product. * Requirement for systemic immunosuppressive therapy within 14 days prior to the first dose of study drug or during the study. * Major surgery (excluding puncture biopsy) within 4 weeks prior to the first dose of study drug, or anticipated need for major surgery during this study. * Uncontrolled active brain metastases or leptomeningeal metastasis. * History of autoimmune disease requiring treatment with corticosteroids or immunosuppressive drugs. * Women in the period of preconception, pregnancy, or lactation. * Any other circumstances which the investigator considers may increase risks to subjects or interfere with the results of the trial.

Inclusion Criteria * Confirmed diagnosis of peripheral neuropathy in the lower extremities by a physician * Lower Extremity Functional Scale (LEFS) score between 0-60 (indicating moderate to significant difficulty in lower extremity function) * Ability to speak and understand English * Ability to provide appropriate written informed consent * Willingness to participate in all study procedures, including the intervention and follow-up visits * Ability to ambulate independently with or without an assistive device Exclusion Criteria * Any medical condition suggesting potential decline in function over the next 6 months (e.g., ongoing chemotherapy, radiation therapy, or dialysis) * Active alcohol or drug misuse * End-stage renal failure * Uncontrolled hypertension * Severe dyslipidemia * Chronic liver disease * Autoimmune disease * Advanced chronic obstructive pulmonary disease (COPD) * Active inflammation * Shingles-related neuropathy * Presence of any lower extremity amputations or significant wounds * Severe chronic medical conditions requiring active treatment that could interfere with study outcomes * Morbid obesity * Concomitant use of medications or devices that may interfere with study results or are not allowed per protocol * Inability to comprehend or provide informed consent * Inability to speak or understand English * Pregnancy, breastfeeding, or planning pregnancy during the study period (female participants) * Inability or unwillingness to adhere to study procedures, including dietary guidelines or follow-up visits * Inability to complete all required study assessments, including follow-up appointments and questionnaires

Inclusion Criteria: 1. Age at time of screening according to diabetes type: 1. T1D: Age 7-85 years 2. T2D: Age 18-85 years 2. Has a clinical diagnosis of diabetes for a minimum per diabetes type below: 1. T1D (Age 7-85 years): Diagnosis of T1D for at least 6 months, as determined via medical record or source documentation by an individual qualified to make a medical diagnosis. 2. T2D (Age 18-85 years): Diagnosis of insulin-requiring T2D for 1 year or more, as determined via medical record or source documentation by an individual qualified to make a medical diagnosis 3. Is willing to provide informed consent/assent for participation. 4. Subject or parent/caregiver is literate and able to read the language (English or Spanish) offered in the study pump or study pump materials. 5. Is willing to wear the system continuously throughout the study. 6. Has results of a retinal eye examination on record prior to enrollment, per guidelines by the American Diabetes Association according to age, duration of diabetes and type of diabetes: 1. T1D adults (Age 18-85 years): I. Initial retinal eye exam within 5 years of diagnosis. II. If the duration of type 1 diabetes is longer than 5 years, a retinal examination should have been performed within the last 12-18 months. 2. T2D adults (Age 18-85 years): I. Results of a retinal eye exam, performed within the last 12-18 months, should be on record. 3. T1D pediatric (Age 7-17 years): I. No exam is required if under the age of 10 years unless the duration of diabetes is more than 3 years. II. For children over the age of 10, a retinal exam should have been performed within 24 months of enrollment in the study. Per the investigator's discretion: If a potential participant is deemed to be at high risk, a retinal eye exam, performed within the last 12 months prior to screening, should be on record. 7. Is willing to upload study pump data via an app or computer. 8. Is willing to take one of the following insulins and can financially support the use of insulin preparations as required by the study: 1. Humalog™\* (insulin lispro injection) 2. NovoLog™\* (insulin aspart solution for injection) or an interchangeable biosimilar (for example, Kirsty™\*) 3. NovoRapid™\* (insulin aspart solution for injection) 4. Admelog™\* (insulin lispro injection) 5. Merilog™\* (insulin aspart) 6. Fiasp™\* (ultra-rapid-acting insulin aspart) 7. Lyumjev™\* (ultra-rapid-acting insulin lispro) 8. Authorized generic insulin aspart 9. Authorized generic insulin lispro Exclusion Criteria: 1. Unable to consent due to a mental or intellectual disability. 2. Has a history of 2 or more episodes of severe hypoglycemia, which resulted in any the following, during the 6 months prior to screening: 1. Medical assistance (i.e., Paramedics, Emergency Room \[ER\] or Hospitalization) 2. Coma or 3. Seizures 3. Has a history of 1 or more episodes of diabetic ketoacidosis (DKA) in the last 6 months prior to screening visit. 4. T2D: Has had hyperglycemic hyperosmolar syndrome (HHS) in the last 6 months prior to screening visit. 5. Has any unresolved adverse skin condition in the area of sensor or infusion set placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection). 6. Currently pregnant or planning to become pregnant during the time period of study participation 1. A negative pregnancy test will be required for all females of child-bearing potential at time of screening 2. For sexually active females of child-bearing potential the investigator will use discretion to determine if the form of contraception that is being used is reliable 7. At investigator discretion, has hypothyroidism or hyperthyroidism that is not adequately treated. 8. Has diagnosis of adrenal insufficiency. 9. Has taken any oral, injectable, or intravenous (IV) glucocorticoids within 8 weeks from time of screening visit. 10. T1D: Is using non-insulin anti-hyperglycemic medication, other than metformin and/or Glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) containing medications (e.g., Mounjaro), in the 8 weeks prior to screening. 1. Participants who have stopped using metformin and/or GLP-1/GIP have done so at least 8 weeks prior to screening. 2. Participants currently taking metformin and/or GLP-1/GIP must be on a steady dose and remain on the same dose during study participation. Dose changes and reasons for changes will be documented throughout the study. 11. T2D: Is using non-insulin anti-hyperglycemic medication, other than metformin, GLP-1 /GIP containing medications (e.g., Mounjaro), or Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors, in the 8 weeks prior to screening. 1. Participants who have stopped using metformin, GLP-1/GIP or SGLT2 have done so at least 8 weeks prior to screening. 2. Participants currently taking metformin, GLP-1/GIP or SGLT2 must be on a steady dose and remain on the same dose during study participation. Dose changes and reasons for changes will be documented throughout the study 12. Is using sulfonylureas and meglitinides, e.g., repaglinide, in the 8 weeks prior to screening. 13. Is using inhalable insulin in the 8 weeks prior to screening. 14. Is using hydroxyurea at time of screening or plans to use it during the study 15. Is participating in another pharmaceutical or device trial within 2 weeks of enrollment or anticipates participation in another trial during the course of the study. 16. Is, at the discretion of the investigator, abusing drugs or alcohol. 17. Is, in the opinion of the investigator, not able to perform all study procedures safely. 18. Has a history of visual impairment which would not allow subject, even with the help of a caregiver, to participate in the study and perform all study procedures safely, as determined by the investigator. 19. Has elective surgery planned that requires general anesthesia during the course of the study. 20. Has sickle cell disease or other hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening. 21. Plans to receive red blood cell transfusion or erythropoietin over the course of study participation. 22. Is diagnosed with current eating disorder such as anorexia or bulimia. 23. Blood disorder or dyscrasia within 3 months prior to screening, which in the investigator's opinion could interfere with determination of HbA1c 24. Is on dialysis. 25. Has an estimated Glomerular Filtration Rate (eGFR) \<30. 26. Has celiac disease that is not adequately treated as determined by the investigator. 27. Has had any of the following cardiovascular events within 1 year of screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, or ventricular rhythm disturbances. 28. Has had any of the following cardiovascular events more than 1 year prior to screening and should not participate at the discretion of the investigator: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, or ventricular rhythm disturbances. 29. Is a member of the research staff involved with the study. 30. Is a Medtronic Diabetes employee or their immediate family member (excluding adult children and/or adult siblings).

Inclusion Criteria: 1. Biologic female 2. 50 years of age and older 3. Confirmed diagnosis of breast cancer: 1. Infiltrating ductal carcinoma 2. ER/PR+Her2neu- 3. Grade I, II, or III 4. Unicentric, unilateral tumor size ≤ 3cm 5. Tumor location ≥ 2 cm from skin and other structures 6. Zubrod Performance Status of 0, 1, or 2 7. No palpable lymphadenopathy 8. Able and willing to provide written informed consent Exclusion Criteria: 1. Pregnant or breastfeeding 2. Neoadjuvant chemotherapy 3. Cardiac arrhythmia 4. Patients with active implantable medical devices, such as implanted cardiac pacemakers or defibrillators, or any other electronic device 5. Current or history of breast implants 6. Multi-centric or bilateral breast cancer 7. Diffuse microcalcifications 8. Participating in another ongoing clinical study in which concomitant diagnostic or therapeutic intervention that would reasonably be expected to alter the outcomes under study 9. Has a condition or is in a situation which in the Investigator's opinion may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study.

Inclusion Criteria: * Have a body mass index (BMI) of: * ≥30 kilogram per square meter (kg/m2) OR * ≥27 kg/m2 with at least one of the following weight-related conditions: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease * Have at least one unsuccessful attempt to lose weight by dieting Exclusion Criteria: * Have a self-reported change in body weight \>5 kg (11 pounds) within 90 days before screening * Have a prior or planned surgical treatment for obesity * Have type 1 diabetes or type 2 diabetes * Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) * Have had within the past 90 days before screening * acute myocardial infarction * cerebrovascular accident (stroke) * hospitalization for unstable angina, or * hospitalization due to congestive heart failure * Have New York Heart Association Functional Classification Class IV congestive heart failure * Have a history of chronic or acute pancreatitis * Have taken weight loss drugs, including over-the counter medications within 90 days prior to screening

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has completed their current respective PAH sotatercept clinical study and its requirements, and must not have discontinued early * Is willing to adhere to the study visit schedule, and understands and will comply with all protocol requirements * Must have the ability to understand and provide documented informed consent Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Did not participate in a sotatercept PAH parent study * Missed more than the equivalent of 4 consecutive doses between the end of parent study and the start of this study. * Presence of an ongoing serious adverse event that occurred during a PAH sotatercept clinical study that is assessed to be possibly or probably related to sotatercept * Is a female who is pregnant or breastfeeding * Is or has an immediate family member who is investigational site or Sponsor staff directly involved with this study * Is currently enrolled in another investigational product study other than a sotatercept study * Is incapacitated

Inclusion Criteria: 1. Reproductive Women ages 18-45 at the time of consent. 2. Diagnosis of non-psychotic Major Depressive Episode (MDE) with peripartum onset as assessed through the Quick Structured Clinical Interview for DSM-5. 3. 0-12 months postpartum. Participants must be 0-12 months postpartum at screening and remain within 12 months postpartum at the 5-day post-treatment visit. 4. If currently taking an antidepressant medication and/or receiving psychotherapy must be on a stable regimen for 30 days at the time of enrollment. 5. Severe depression as measured by MADRS ≥20 at screening. 6. A good candidate for repetitive transcranial magnetic stimulation (rTMS) as determined by a physician. 7. Participants must be capable of giving informed consent. Participants must be proficient in English in order to comprehend study requirements. 8. Agree to use effective contraception in the postpartum period for the study duration. 9. Willing and able to comply with all study procedures, complete required assessments and visits, and be available for the duration of the study. Exclusion Criteria: 1. Participant has attempted suicide in the last 6 months and/or expressed suicidal ideation with intent as determined by physician assessment at the time of enrollment. 2. Score of 6 on MADRS item 10 (high rating of suicidal ideation) at screening. 3. Participant has active psychosis per investigator assessment. 4. Participant with a primary lifetime diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder and/or obsessive-compulsive disorder. 5. Participant has an active eating disorder or substance use disorder in the past 6 months and/or has a positive urine toxicity screen that the Principal Investigator (PI) deems exclusionary. 6. Participant is using any exclusionary medications: high dose of benzodiazepines (\>2mg lorazepam daily equivalent and/or \>3 times per week) or medications that would interfere with treatment with TMS as per PI or designee discretion. 7. Participant has a history of untreated or insufficiently treated sleep apnea. 8. Participant has a history of significant neurologic disease, including developmental disability, dementia, Parkinson's or Huntington's disease, brain tumor, unexpected seizure/epilepsy disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma. 9. Any untreated major somatic illness such as hypertension/cardiovascular disease/diabetes/endocrine disorders etc. 10. Contraindications to receiving rTMS (e.g., metal in head, history of seizure, known brain lesion). 11. Contraindications to MRI (e.g., ferromagnetic metal in their body). 12. Currently pregnant. 13. History of receiving rTMS for any reason, as this may compromise blinding.